Business
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders NAPLES, Fla., March
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders \nNAPLES, Fla., March 15, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) (\"Enveric\" or the \"Company\"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that the Company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization (WIPO). Additional PCT patent applications are expected to publish over the coming months.\n\"Tryptamine represents the core structural motif for numerous intriguing therapeutically active agents such as the classic psychedelic molecules N, N-dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT. Many of these molecules are being investigated worldwide as potential treatments for a broad range of psychiatric and neurologic disorders, including mood and anxiety disorders, post-traumatic stress disorder, cancer-related distress and more,1,2\" said Bob Dagher, MD, Enveric's Chief Medical Officer. \"These patent applications aim to protect Enveric's assets of new drug candidates and place our discovery engine at the forefront of bringing forward innovative psychiatric and neurologic therapeutics of the future.\"\nTryptamine is a classic psychedelic molecule that binds to and activates serotonin and other receptors in the brain.1,2 The tryptamine class includes psilocybin, psilocin, and dimethyltryptamine (DMT), which are naturally occurring psychedelics that are currently under intense study for therapeutic applications.1 Based on recent and emerging data, the Company believes this class of molecules may have the potential to produce rapid, profound, and long-lasting benefits for a broad range of indications.\nThe published PCT patent applications protecting Enveric's novel tryptamine-derived molecules, as well as the respective Written Opinion of the International Searching Authority for each application, are available for review on the WIPO website. \nReferences:\nSzabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Frontiers Immunol. 2015;6:358. doi: 10.3389/fimmu.2015.00358Castelhano J, Lima G, Teixeira M, Soares...